Perianal fistulas are defined as pathological connections between the anorectal canal and the perianal skin. Most perianal fistulas are cryptoglandular fistulas, which are thought to originate from infected anal glands. The remainder of the fistulas mainly arises as complications of Crohn’s disease (CD), trauma, or as a result of malignancies. Fistulas in CD are considered as a consequence of a chronic and transmural inflammatory process in the distal bowel and can, in some cases, even precede the diagnosis of CD. Although both cryptoglandular and CD-associated fistulas might look similar macroscopically, they differ considerably in their complexity, treatment options, and healing rate. Therefore, it is of crucial importance to differentiate between these two types of fistulas. In this review, the differences between CD-associated and cryptoglandular perianal fistulas in epidemiology, pathogenesis, and clinical management are discussed. Finally, a flow chart is provided for physicians to guide them when dealing with patients displaying their first episode of perianal fistulas.
BACKGROUND: Due to their immunoregulatory and tissue regenerative features, mesenchymal stromal cells (MSCs) are a promising novel tool for the management of ulcerative proctitis (UP). Here we report on a phase IIa clinical study that evaluated the impact of local MSC therapy on UP. METHODS: Thirteen refractory UP patients, with an endoscopic Mayo score (EMS) of 2 or 3, were included. Seven patients received 20–40 million allogeneic MSCs (cohort 1), while 6 patients received 40–80 million MSCs (cohort 2). Adverse events (AEs) were assessed at baseline and on weeks 2, 6, 12, and 24. Clinical, endoscopic, and biochemical parameters were assessed at baseline and on weeks 2 and 6. Furthermore, we evaluated the engraftment of MSCs, the presence of donor-specific human leukocyte antigen (HLA) antibodies (DSAs), and we determined the impact of MSC therapy on the local immune compartment. RESULTS: No serious AEs were observed. The clinical Mayo score was significantly improved on weeks 2 and 6, and the EMS was significantly improved on week 6, compared with baseline. On week 6, donor MSCs were still detectable in rectal biopsies from 4 of 9 patients and DSAs against both HLA class I and class II were found. Mass cytometry showed a reduction in activated CD8 + T cells and CD16 + monocytes and an enrichment in mononuclear phagocytes and natural killer cells in biopsies after local MSC therapy. CONCLUSION: Local administration of allogeneic MSCs is safe, tolerable, and feasible for treatment of refractory UP and shows encouraging signs of clinical efficacy and modulation of local immune responses. This sets the stage for larger clinical trials. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT, 2017-003524-75) and the Dutch Trial Register (NTR7205). FUNDING: ECCO grant 2020.
We applied high-dimensional analyses to profile the immune compartment in CD-associated and cryptoglandular perianal fistulas. Data analysis revealed activated HLA-DR+CD38+ effector Th1/17 cells as distinctly increased in CD-associated fistulas, suggesting a potential novel therapeutic target.
CD4⁺ T helper (Th) cell responses to commensal microbiota are linked to Inflammatory Bowel Disease (IBD), yet how Th programs coexist and evolve in human tissues remains poorly defined. Here, we profiled CD4⁺ memory T cells in intestinal biopsies using immunological and histological approaches to map their phenotypes, functional states, and spatial relationships across disease states. A marked expansion of CD4⁺ T cells concomitant with a RORγt⁺ Th population with elevated T-bet expression was linked to progression of inflammation. Moreover, Foxp3⁺ cells co-expressing RORγt emerged within the inflamed niche, indicating regulatory–Th17 plasticity. Trajectory visualization revealed a potential branched differentiation path towards either regulatory or tissue-resident Th17-like fates, with both termini expressing activation and proliferation markers. Correlation network analysis connected pro-inflammatory CD4⁺ states to T-bet⁺Granzyme-B⁺ CD8⁺ subsets, indicative of crosstalk between helper and cytotoxic lineages. Histology corroborated this organization, showing frequent interactions between CD4⁺ and CD8⁺ cells in the lamina propria and epithelial border. In functional assays, TCR stimulation during active disease revealed broad suppression of CD4⁺ pro-inflammatory cytokines concomitant with expansion of Foxp3⁺ cells. Conversely, HLA-DR + CD38 + memory subset retained multifunctionality, producing elevated levels of pro-inflammatory cytokines. Together, these results provide insight into a dynamic, tissue-embedded CD4 landscape in IBD. Highlights: IBD inflammation shapes CD4 + T-cell plasticity and tissue-residency programming. Correlated CD4 + and cytotoxic CD8 + T cells co-localize in inflamed mucosa. Mucosal CD4⁺ memory T cells show hypo-responsiveness in active IBD. HLA-DR + CD38 + memory CD4⁺ T cells amplify inflammation via cytokine output.